Abdulraheem Yacoub, MD
Hematology-Oncology · Westwood, KSNPI 1639372766
Payments from drug & device makers
Across 1,758 payments — averaging $4735.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$3.4M
- Pfizer$882K
- Stemline Therapeutics Inc.$805K
- Otsuka Pharmaceutical Co., Ltd.$687K
- Pharmaessentia USA Corporation$611K
- Genentech, Inc.$553K
- plus $1.4M from 26 others
Across 7 payments — averaging $843.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3K
- F. Hoffmann-la Roche AG$2K
- Pfizer$330
- Novartis$274
What the payments were for
- Consulting fees$163,58351%
- Speaking & faculty fees$123,09138%
- Travel & lodging$25,7788%
- Food & beverage$7,2062%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 1,144 | $3,384,335 |
| Pfizer | 42 | $882,435 |
| Stemline Therapeutics Inc. | 93 | $804,751 |
| Otsuka Pharmaceutical Co., Ltd. | 67 | $687,450 |
| Pharmaessentia USA Corporation | 57 | $611,305 |
| Genentech, Inc. | 19 | $553,088 |
| Bristol Myers Squibb | 27 | $502,382 |
| Blueprint Medicines Corporation | 33 | $209,125 |
| Seagen Inc. | 39 | $152,869 |
| CTI Biopharma Corp. | 17 | $99,577 |
| Taiho Oncology, Inc. | 92 | $93,721 |
| AbbVie | 32 | $77,476 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $71,893 |
| Helsinn Healthcare SA | 6 | $52,982 |
| Gilead | 10 | $40,365 |
| Janssen Research & Development, LLC | 1 | $26,829 |
| E.r. Squibb & Sons, L.L.C. | 5 | $17,392 |
| Novartis | 9 | $15,459 |
| GSK | 10 | $10,944 |
| Servier Pharmaceuticals LLC | 3 | $6,199 |
| Sobi, Inc | 2 | $4,270 |
| Geron Corporation | 5 | $4,072 |
| Ipsen Innovation | 2 | $3,185 |
| Sanofi US Services Inc. | 1 | $2,948 |
| Syndax Pharmaceuticals, Inc. | 5 | $2,725 |
| Agios Pharmaceuticals, Inc. | 3 | $2,555 |
| Genmab U.S., Inc. | 2 | $1,570 |
| ADC Therapeutics America, Inc. | 1 | $1,400 |
| Acceleron Pharma, Inc. | 1 | $845 |
| Karyopharm Therapeutics Inc. | 1 | $815 |
| AstraZeneca | 2 | $275 |
| Genentech USA, Inc. | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 159 | $2,586,151 |
| OjjaaraMomelotinib Dihydrochloride | 58 | $1,535,303 |
| AyvakitAvapritinib | 33 | $1,282,223 |
| ScemblixAsciminib Hydrochloride | 23 | $1,167,849 |
| PromactaEltrombopag Olamine | 37 | $889,037 |
| FabhaltaIptacopan Hcl | 15 | $661,687 |
| IdhifaEnasidenib Mesylate | 16 | $510,893 |
| PegasysPeginterferon Alfa-2a | 77 | $231,747 |
| CalquenceAcalabrutinib Maleate | 18 | $226,382 |
| TasignaNilotinib Hcl | 17 | $216,787 |
| ImbruvicaIbrutinib | 12 | $196,384 |
| SprycelDasatinib | 27 | $167,988 |
| VenclextaVenetoclax | 28 | $81,004 |
| Imatinib Mesylate | 77 | $15,345 |
| Atovaquone | 12 | $4,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisScemblix, Promacta, Fabhalta, Tasigna | $15,459 | $2,935,36092 claims |
| Incyte CorporationJakafi | $3,384,335 | $2,586,151159 claims |
| GSKOjjaara | $10,944 | $1,535,30358 claims |
| Blueprint Medicines CorporationAyvakit | $209,125 | $1,282,22333 claims |
| Bristol Myers SquibbIdhifa | $502,382 | $510,89316 claims |
| Genentech, Inc.Pegasys | $553,088 | $231,74777 claims |
| AstraZenecaCalquence | $275 | $226,38218 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $17,392 | $167,98827 claims |
| AbbVieVenclexta | $77,476 | $81,00428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Kansason file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.